AKT1 and non-small cell lung carcinoma: However, synergistic effects of the combination therapy were observed in the gefitinib-resistant PC9/GR human NSCLC cell line, and a significant decrease in the phosphorylation level of AKT was observed, demonstrating a significantly enhanced anti-proliferative effect (38).